Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.13 (market cap $162.00B), while Neurocrine Biosciences Inc trades at $142.79 (market cap $14.36B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 11.3× Neurocrine Biosciences Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IEMG | NBIX | |
|---|---|---|
Market Cap | $162.00B | $14.36B |
Volume | 13,446,151 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $185.50 |
52-Week Low | $64.22 | $123.10 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.14, down 1.1% with a bearish technical signal from moving averages. The ETF's emerging markets focus has delivered strong recent performance, with articles highlighting 35% one-year returns and record asset inflows. Technical indicators show neutral oscillators but bearish momentum, with key support at $79 and resistance at $82.
Emerging markets exposure offers growth potential amid dollar weakness, though higher volatility and expense ratios compared to developed market ETFs present risks. The fund's 39% technology weighting and outperformance versus peers like SCHE and VWO provide differentiation, but concentration risks and market sensitivity require careful monitoring.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
